RHK Stock Overview
Offers in-patient, semi-patient, and outpatient healthcare services in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RHK from our risk checks.
RHÖN-KLINIKUM Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.00 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | -0.11 |
| 11 Month Change | 0% |
| 3 Month Change | -2.99% |
| 1 Year Change | -2.99% |
| 33 Year Change | -2.80% |
| 5 Year Change | -2.80% |
| Change since IPO | -9.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| RHK | CH Healthcare | CH Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.4% |
| 1Y | -3.0% | 5.3% | 4.8% |
Return vs Industry: RHK underperformed the Swiss Healthcare industry which returned 5.3% over the past year.
Return vs Market: RHK underperformed the Swiss Market which returned 4.8% over the past year.
Price Volatility
| RHK volatility | |
|---|---|
| RHK Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine RHK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 18,507 | Tobias Kaltenbach | www.rhoen-klinikum-ag.com |
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. It also operates acute hospitals, medical care centers, and rehabilitation hospitals. The company was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.
RHÖN-KLINIKUM Aktiengesellschaft Fundamentals Summary
| RHK fundamental statistics | |
|---|---|
| Market cap | CHF 785.65m |
| Earnings (TTM) | CHF 41.79m |
| Revenue (TTM) | CHF 1.71b |
18.8x
P/E Ratio0.5x
P/S RatioIs RHK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHK income statement (TTM) | |
|---|---|
| Revenue | €1.84b |
| Cost of Revenue | €1.62b |
| Gross Profit | €211.75m |
| Other Expenses | €166.88m |
| Earnings | €44.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 11.54% |
| Net Profit Margin | 2.44% |
| Debt/Equity Ratio | 10.9% |
How did RHK perform over the long term?
See historical performance and comparison